Cargando…
Beyond clinical trials: Evolutionary and epidemiological considerations for development of a universal influenza vaccine
The prospect of universal influenza vaccines is generating much interest and research at the intersection of immunology, epidemiology, and viral evolution. While the current focus is on developing a vaccine that elicits a broadly cross-reactive immune response in clinical trials, there are important...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7514029/ https://www.ncbi.nlm.nih.gov/pubmed/32970783 http://dx.doi.org/10.1371/journal.ppat.1008583 |
_version_ | 1783586493250404352 |
---|---|
author | Viboud, Cécile Gostic, Katelyn Nelson, Martha I. Price, Graeme E. Perofsky, Amanda Sun, Kaiyuan Sequeira Trovão, Nídia Cowling, Benjamin J. Epstein, Suzanne L. Spiro, David J. |
author_facet | Viboud, Cécile Gostic, Katelyn Nelson, Martha I. Price, Graeme E. Perofsky, Amanda Sun, Kaiyuan Sequeira Trovão, Nídia Cowling, Benjamin J. Epstein, Suzanne L. Spiro, David J. |
author_sort | Viboud, Cécile |
collection | PubMed |
description | The prospect of universal influenza vaccines is generating much interest and research at the intersection of immunology, epidemiology, and viral evolution. While the current focus is on developing a vaccine that elicits a broadly cross-reactive immune response in clinical trials, there are important downstream questions about global deployment of a universal influenza vaccine that should be explored to minimize unintended consequences and maximize benefits. Here, we review and synthesize the questions most relevant to predicting the population benefits of universal influenza vaccines and discuss how existing information could be mined to begin to address these questions. We review three research topics where computational modeling could bring valuable evidence: immune imprinting, viral evolution, and transmission. We address the positive and negative consequences of imprinting, in which early childhood exposure to influenza shapes and limits immune responses to future infections via memory of conserved influenza antigens. However, the mechanisms at play, their effectiveness, breadth of protection, and the ability to “reprogram” already imprinted individuals, remains heavily debated. We describe instances of rapid influenza evolution that illustrate the plasticity of the influenza virus in the face of drug pressure and discuss how novel vaccines could introduce new selective pressures on the evolution of the virus. We examine the possible unintended consequences of broadly protective (but infection-permissive) vaccines on the dynamics of epidemic and pandemic influenza, compared to conventional vaccines that have been shown to provide herd immunity benefits. In conclusion, computational modeling offers a valuable tool to anticipate the benefits of ambitious universal influenza vaccine programs, while balancing the risks from endemic influenza strains and unpredictable pandemic viruses. Moving forward, it will be important to mine the vast amount of data generated in clinical studies of universal influenza vaccines to ensure that the benefits and consequences of these vaccine programs have been carefully modeled and explored. |
format | Online Article Text |
id | pubmed-7514029 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-75140292020-10-01 Beyond clinical trials: Evolutionary and epidemiological considerations for development of a universal influenza vaccine Viboud, Cécile Gostic, Katelyn Nelson, Martha I. Price, Graeme E. Perofsky, Amanda Sun, Kaiyuan Sequeira Trovão, Nídia Cowling, Benjamin J. Epstein, Suzanne L. Spiro, David J. PLoS Pathog Review The prospect of universal influenza vaccines is generating much interest and research at the intersection of immunology, epidemiology, and viral evolution. While the current focus is on developing a vaccine that elicits a broadly cross-reactive immune response in clinical trials, there are important downstream questions about global deployment of a universal influenza vaccine that should be explored to minimize unintended consequences and maximize benefits. Here, we review and synthesize the questions most relevant to predicting the population benefits of universal influenza vaccines and discuss how existing information could be mined to begin to address these questions. We review three research topics where computational modeling could bring valuable evidence: immune imprinting, viral evolution, and transmission. We address the positive and negative consequences of imprinting, in which early childhood exposure to influenza shapes and limits immune responses to future infections via memory of conserved influenza antigens. However, the mechanisms at play, their effectiveness, breadth of protection, and the ability to “reprogram” already imprinted individuals, remains heavily debated. We describe instances of rapid influenza evolution that illustrate the plasticity of the influenza virus in the face of drug pressure and discuss how novel vaccines could introduce new selective pressures on the evolution of the virus. We examine the possible unintended consequences of broadly protective (but infection-permissive) vaccines on the dynamics of epidemic and pandemic influenza, compared to conventional vaccines that have been shown to provide herd immunity benefits. In conclusion, computational modeling offers a valuable tool to anticipate the benefits of ambitious universal influenza vaccine programs, while balancing the risks from endemic influenza strains and unpredictable pandemic viruses. Moving forward, it will be important to mine the vast amount of data generated in clinical studies of universal influenza vaccines to ensure that the benefits and consequences of these vaccine programs have been carefully modeled and explored. Public Library of Science 2020-09-24 /pmc/articles/PMC7514029/ /pubmed/32970783 http://dx.doi.org/10.1371/journal.ppat.1008583 Text en https://creativecommons.org/publicdomain/zero/1.0/ This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 (https://creativecommons.org/publicdomain/zero/1.0/) public domain dedication. |
spellingShingle | Review Viboud, Cécile Gostic, Katelyn Nelson, Martha I. Price, Graeme E. Perofsky, Amanda Sun, Kaiyuan Sequeira Trovão, Nídia Cowling, Benjamin J. Epstein, Suzanne L. Spiro, David J. Beyond clinical trials: Evolutionary and epidemiological considerations for development of a universal influenza vaccine |
title | Beyond clinical trials: Evolutionary and epidemiological considerations for development of a universal influenza vaccine |
title_full | Beyond clinical trials: Evolutionary and epidemiological considerations for development of a universal influenza vaccine |
title_fullStr | Beyond clinical trials: Evolutionary and epidemiological considerations for development of a universal influenza vaccine |
title_full_unstemmed | Beyond clinical trials: Evolutionary and epidemiological considerations for development of a universal influenza vaccine |
title_short | Beyond clinical trials: Evolutionary and epidemiological considerations for development of a universal influenza vaccine |
title_sort | beyond clinical trials: evolutionary and epidemiological considerations for development of a universal influenza vaccine |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7514029/ https://www.ncbi.nlm.nih.gov/pubmed/32970783 http://dx.doi.org/10.1371/journal.ppat.1008583 |
work_keys_str_mv | AT viboudcecile beyondclinicaltrialsevolutionaryandepidemiologicalconsiderationsfordevelopmentofauniversalinfluenzavaccine AT gostickatelyn beyondclinicaltrialsevolutionaryandepidemiologicalconsiderationsfordevelopmentofauniversalinfluenzavaccine AT nelsonmarthai beyondclinicaltrialsevolutionaryandepidemiologicalconsiderationsfordevelopmentofauniversalinfluenzavaccine AT pricegraemee beyondclinicaltrialsevolutionaryandepidemiologicalconsiderationsfordevelopmentofauniversalinfluenzavaccine AT perofskyamanda beyondclinicaltrialsevolutionaryandepidemiologicalconsiderationsfordevelopmentofauniversalinfluenzavaccine AT sunkaiyuan beyondclinicaltrialsevolutionaryandepidemiologicalconsiderationsfordevelopmentofauniversalinfluenzavaccine AT sequeiratrovaonidia beyondclinicaltrialsevolutionaryandepidemiologicalconsiderationsfordevelopmentofauniversalinfluenzavaccine AT cowlingbenjaminj beyondclinicaltrialsevolutionaryandepidemiologicalconsiderationsfordevelopmentofauniversalinfluenzavaccine AT epsteinsuzannel beyondclinicaltrialsevolutionaryandepidemiologicalconsiderationsfordevelopmentofauniversalinfluenzavaccine AT spirodavidj beyondclinicaltrialsevolutionaryandepidemiologicalconsiderationsfordevelopmentofauniversalinfluenzavaccine |